Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 2270 • ACR Convergence 2022
Evidence for Mitochondrial Dysfunction in Blood-derived Endothelial Colony Forming Cells Isolated from Patients with Antiphospholipid Syndrome
Lida Kabir, Robert Maughan, Koralia Paschalaki, Anna Randi, David Carling, Deepa Arachchillage, Justin Mason and Charis Pericleous, Imperial College London, London, United Kingdom
Background/Purpose: The endothelium is a major target of pathogenic antiphospholipid antibodies (aPL) found in patients with antiphospholipid syndrome (APS). It is well established that aPL…
Abstract Number: 0673 • ACR Convergence 2022
Occurrence and Severity of Bleeding in Adults with Immunogenic Thrombocytopenic Purpura with or Without Antiphospholipid Autoantibodies
Izabella Elgardt¹, Or Carmi², Wakar Garra³ and Yair Levy⁴, ¹Sackler Faculty of Medicine, Tel Aviv University, 69978, Israel Department of Internal Medicine E, Meir Medical Center, Kefar Sava, Israel, ²Meir Hospital, Kfar Saba, Israel, ³Sackler Faculty of Medicine, Tel Aviv University, 69978, Israel Department of Internal Medicine E, Meir Medical Center, Kfar Saba, Israel, ⁴Meir Medical Center, Gany Tikva, Israel
Background/Purpose: ITP is an autoimmune disease defined as an isolated platelet count. It may be asymptomatic or accompanied by varying degrees of bleeding. APS is…
Abstract Number: 0689 • ACR Convergence 2022
Type I Interferon Stimulated Genes Identify Different Phenotypes of Antiphospholipid Syndrome Patients
Irene Cecchi¹, Massimo Radin², Alice Barinotti², Silvia Grazietta Foddai², Elena Rubini², Ana Suárez³, Simone Baldovino², Elisa Menegatti², Dario Roccatello², Savino Sciascia¹ and Javier Rodríguez-Carrio⁴, ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy, ³University of Oviedo, Oviedo, Spain, ⁴University of Oviedo,, Oviedo, Spain
Background/Purpose: At present, a limited number of evidencesis available on the specific role of Type I Interferons (IFN) activation in antiphospholipid antibodies (aPL) positive patients,…
Abstract Number: 2271 • ACR Convergence 2022
Circulating Calprotectin: A Potential New Biomarker for “Non-Criteria” Clinical Manifestations of Antiphospholipid Syndrome
Claire Hoy¹, Naveen Kumar S K¹, Sherwin Navaz¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Noah Peters¹, Tristin Smith¹, Gary Norman³, Gabriel Figueroa Parra⁴, Johann Gudjonsson¹, J. Michelle Kahlenberg¹, Jacqueline Madison¹, Ali Duarte-Garcia⁴, Jason S Knight⁵ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³INOVA Diagnostics, San Diego, CA, ⁴Mayo Clinic, Rochester, MN, ⁵University of Michigan, Division of Rheumatology, Ann Arbor, MI

Background/Purpose: While thrombosis and pregnancy loss are the best-known features of APS, many patients also exhibit "non-criteria" manifestations such as thrombocytopenia and heart valve damage.…
Abstract Number: 0674 • ACR Convergence 2022
Prevalence of Heparin Induced Thrombocytopenia in Hospitalized Patients with Antiphospholipid Syndrome or Systemic Lupus Erythematosus with Antiphospholipid Antibodies
Vincent Tran, Amy Schmitt and Shanthini Kasturi, Tufts Medical Center, Boston, MA
Background/Purpose: Thrombosis and thrombocytopenia are defining characteristics of antiphospholipid syndrome (APS), but can also be seen in heparin-induced thrombocytopenia (HIT). Hospitalized patients with APS are…
Abstract Number: 0690 • ACR Convergence 2022
The Physiological Ketone Body Beta-Hydroxybutyrate Potently Neutralizes APS-Associated NETosis
Ajay Tambralli¹, Alyssa Harbaugh¹, Christine Rysenga¹, Kaitlyn Sabb¹, Srilakshmi Yalavarthi¹, Claire Hoy¹, Yu (Ray) Zuo¹ and Jason S Knight², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Malleable metabolic pathways guide both productive and pathological neutrophil functions, including neutrophil extracellular trap release (NETosis). NETosis plays an important role in APS pathophysiology.…
Abstract Number: 0675 • ACR Convergence 2022
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Hannah Langenfeld², Rodrigo Cartin-Ceba¹, Ulrich Specks¹, Cynthia Crowson³ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN
Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…
Abstract Number: 0691 • ACR Convergence 2022
Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls
Hannah Britt¹, Hannah Bradford¹, Valentina Spiteri¹, Anisur Rahman², Ian Giles¹, Mihaela Delcea³, Paul Dalby¹, Kostas Thalassinos¹ and Thomas McDonnell¹, ¹University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³University of Greifswald, Greifswald, Germany
Background/Purpose: Beta-2-Glycoprotein I (B2GPI) is a serum protein of approximately 50kDa and is the main autoantigen of Antiphospholipid syndrome (APS). Antibodies to B2GPI (aB2GPI) are…
Abstract Number: 0676 • ACR Convergence 2022
Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Jeffrey X. Yang¹, Hannah Langenfeld², Prerna Dogra¹, Irina Bancos³, Hassan Murad³, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with antiphospholipid syndrome (APS) and adrenal hemorrhage (AH).Methods: We performed a multicenter retrospective cohort…
Abstract Number: 0692 • ACR Convergence 2022
The Interplay Between Lipid Peroxidation and Neutrophil Extracellular Trap (NET) Formation in APS Pathogenesis
Naveen Kumar S K¹, Claire Hoy¹, Christine Rysenga¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Sherwin Navaz¹, Jacqueline Madison¹, Jason S Knight³ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Lipid peroxidation is the result of disrupted redox homeostasis and functions as a key component in various cell death programs. Neutrophil extracellular trap (NET)…
Abstract Number: 0677 • ACR Convergence 2022
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Gustavo Balbi¹, Flavio Victor Signorelli², Ana Paula Gandara³, Indira Azam³, Dilson Marreiros³, Luciano Drager³ and Danieli Castro Oliveira de Andrade⁴, ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ³University of São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
Abstract Number: 0693 • ACR Convergence 2022
Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
Naveen Kumar S K¹, Claire Hoy¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Kaitlyn Sabb¹, Christine Rysenga¹, Jacqueline Madison¹, Yu Zuo¹ and Jason S Knight³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: By converting extracellular ATP into homeostatic adenosine, the ectonucleotidases CD39 (ATP to AMP) and CD73 (AMP to adenosine) dictate extracellular purinergic gradients and as…
Abstract Number: 0678 • ACR Convergence 2022
Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019
Patompong Ungprasert¹, Sunisa Kongkiatkamon², Ben Ponvilawan³, Nuttavut Sumransub⁴ and Paul Kroner⁵, ¹Cleveland Clinic, Cleveland Heights, OH, ²Chulalongkorn University, Bangkok, Thailand, ³Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, ⁴University of Minnesota, Minneapolis, MN, ⁵Mayo Clinic, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, morbidity, mortality and resource utilization of patients with antiphospholipid syndrome (APS). The purpose of this study is to…
Abstract Number: 0694 • ACR Convergence 2022
Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis
Maria Laura Bertolaccini¹, Yiannis Ioannou², Helen Neale³, Prakash Saha¹ and Alberto Smith¹, ¹King's College London, London, United Kingdom, ²UCB Biopharma SRL, London, United Kingdom, ³UCB Biopharma SRL, Slough, United Kingdom
Background/Purpose: FcRn (the neonatal Fc receptor) is a receptor expressed by antigen-presenting cells, such as monocytes, macrophages, and dendritic cells, as well as on neutrophils.…
Abstract Number: 0679 • ACR Convergence 2022
Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample 
Faria Sami, Dennis Kumi and Shilpa Arora, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Antiphospholipid antibody syndrome (APLS) is strongly associated with the risk of cardiovascular events including acute coronary syndrome (ACS). However, there is limited data on…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].